<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2183-5985</journal-id>
<journal-title><![CDATA[Acta Portuguesa de Nutrição]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Port Nutr]]></abbrev-journal-title>
<issn>2183-5985</issn>
<publisher>
<publisher-name><![CDATA[Associação Portuguesa de Nutrição]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2183-59852015000400005</article-id>
<article-id pub-id-type="doi">10.21011/apn.2015.0305</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Terapêutica Nutricional na Artrite Reumatóide]]></article-title>
<article-title xml:lang="en"><![CDATA[Nutritional Approach of Rheumatoid Arthritis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pinheiro]]></surname>
<given-names><![CDATA[Joana]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Termas de S. Jorge  ]]></institution>
<addr-line><![CDATA[Caldas de S. Jorge ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2015</year>
</pub-date>
<numero>3</numero>
<fpage>26</fpage>
<lpage>30</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2183-59852015000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2183-59852015000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2183-59852015000400005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[A artrite reumatoide é uma doença autoimune crónica caraterizada por sinovites extensas resultando na erosão da cartilagem articular e perda de osso marginal que levam à destruição da articulação. Indivíduos com artrite reumatoide têm tendência para um mau estado nutricional. Para além disso, alguns dos fármacos utilizados na sua terapêutica aumentam as necessidades de alguns nutrientes e, noutros casos, reduzem a sua absorção. Com este trabalho pretende-se fazer um resumo da informação científica disponível sobre o papel da alimentação e dos principais nutrientes mais indicados como complemento do tratamento da artrite reumatoide, nomeadamente na redução da sintomatologia, na progressão da doença e de efeitos secundários associados à toma dos fármacos recomendados. Apesar de já existir alguma evidência da utilidade da nutrição como complemento da terapêutica na artrite reumatoide, são necessários mais estudos para determinar as necessidades nutricionais ótimas para os indivíduos com artrite reumatoide, assim como comprovar os benefícios da suplementação nutricional específica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Rheumatoid arthritis is a chronic autoimmune disease characterized by extensive synovitis resulting in erosion of articular cartilage and marginal bone that lead to joint destruction. It&#8217;s common to patients with rheumatoid arthritis to have poor nutritional status. Furthermore, some of the drugs used in its treatment can increase the requirements of some nutrients in some cases or reduce their absorption in other cases. The objective of this paper is to review the scientific information of the importance of dietary patterns and the main nutrients recommended as complement for the treatment of rheumatoid arthritis in the reduction of symptomatology, the progression of the disease and the side effects associated to the drugs recommended. Although there is some evidence of the nutrition utility as complement of rheumatoid arthritis therapy, more studies are needed to determine the best nutritional needs in this disease, as well as to prove the benefits of nutritional supplements use.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Ácidos gordos polinsaturados n-3]]></kwd>
<kwd lng="pt"><![CDATA[Alimentação]]></kwd>
<kwd lng="pt"><![CDATA[Antioxidantes]]></kwd>
<kwd lng="pt"><![CDATA[Artrite reumatoide]]></kwd>
<kwd lng="pt"><![CDATA[Probióticos]]></kwd>
<kwd lng="en"><![CDATA[n-3 polyunsaturated fatty acids]]></kwd>
<kwd lng="en"><![CDATA[Dietary patterns]]></kwd>
<kwd lng="en"><![CDATA[Antioxidants]]></kwd>
<kwd lng="en"><![CDATA[Rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[Probiotics]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><b>ARTIGO DE REVIS&#195;O</b></p>     <p><b>Terap&ecirc;utica Nutricional na Artrite Reumat&oacute;ide</b></p>     <p><b>Nutritional Approach of Rheumatoid Arthritis</b></p>     <p>&nbsp;</p>     <p><b>Joana Pinheiro<sup>1</sup></b></p>     <p><sup>1</sup>Termas de S. Jorge, Caldas de S. Jorge, Lugar da S&eacute;, 4509-903 Caldas de S. Jorge, Portugal</p>     <p><a href="#c0">Endere&#231;o para correspond&#234;ncia</a><a name="topc0"></a></b></p>     <p>&nbsp;</p>     <p><b >RESUMO</b></p>     <p>A artrite reumatoide &eacute; uma doen&ccedil;a autoimune cr&oacute;nica caraterizada por sinovites extensas resultando na eros&atilde;o da cartilagem articular e perda de osso marginal que levam &agrave; destrui&ccedil;&atilde;o da articula&ccedil;&atilde;o. Indiv&iacute;duos com artrite reumatoide t&ecirc;m tend&ecirc;ncia para um mau estado nutricional. Para al&eacute;m disso, alguns dos f&aacute;rmacos utilizados na sua terap&ecirc;utica aumentam as necessidades de alguns nutrientes e, noutros casos, reduzem a sua absor&ccedil;&atilde;o.</p>     ]]></body>
<body><![CDATA[<p>Com este trabalho pretende-se fazer um resumo da informa&ccedil;&atilde;o cient&iacute;fica dispon&iacute;vel sobre o papel da alimenta&ccedil;&atilde;o e dos principais nutrientes mais indicados como complemento do tratamento da artrite reumatoide, nomeadamente na redu&ccedil;&atilde;o da sintomatologia, na progress&atilde;o da doen&ccedil;a e de efeitos secund&aacute;rios associados &agrave; toma dos f&aacute;rmacos recomendados.</p>     <p>Apesar de j&aacute; existir alguma evid&ecirc;ncia da utilidade da nutri&ccedil;&atilde;o como complemento da terap&ecirc;utica na artrite reumatoide, s&atilde;o necess&aacute;rios mais estudos para determinar as necessidades nutricionais &oacute;timas para os indiv&iacute;duos com artrite reumatoide, assim como comprovar os benef&iacute;cios da suplementa&ccedil;&atilde;o nutricional espec&iacute;fica.</p>     <p><b>Palavras-Chave:</b> &Aacute;cidos gordos polinsaturados n-3, Alimenta&ccedil;&atilde;o, Antioxidantes, Artrite reumatoide, Probi&oacute;ticos</p>     <p>&nbsp;</p>  <hr>     <p>&nbsp;</p>     <p><b>ABSTRACT</b></p>     <p>Rheumatoid arthritis is a chronic autoimmune disease characterized by extensive synovitis resulting in erosion of articular cartilage and marginal bone that lead to joint destruction. It&rsquo;s common to patients with rheumatoid arthritis to have poor nutritional status. Furthermore, some of the drugs used in its treatment can increase the requirements of some nutrients in some cases or reduce their absorption in other cases.</p>     <p>The objective of this paper is to review the scientific information of the importance of dietary patterns and the main nutrients recommended as complement for the treatment of rheumatoid arthritis in the reduction of symptomatology, the progression of the disease and the side effects associated to the drugs recommended.</p>     <p>Although there is some evidence of the nutrition utility as complement of rheumatoid arthritis therapy, more studies are needed to determine the best nutritional needs in this disease, as well as to prove the benefits of nutritional supplements use.</p>     <p><b>Keywords:</b> n-3 polyunsaturated fatty acids, Dietary patterns, Antioxidants, Rheumatoid arthritis, Probiotics</p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p> <hr>     <p>&nbsp;</p>     <p><b>INTRODU&Ccedil;&Atilde;O</b></p>     <p>A artrite reumat&oacute;ide (AR) &eacute; uma doen&ccedil;a autoimune, onde existe uma inflama&ccedil;&atilde;o cr&oacute;nica das estruturas articulares e periarticulares. Manifesta-se pela exist&ecirc;ncia de articula&ccedil;&otilde;es tumefactas, dor, altera&ccedil;&atilde;o da capacidade funcional e fadiga muscular, bem como por uma maior predisposi&ccedil;&atilde;o para a doen&ccedil;a cardiovascular e osteoporose (1-3). &Eacute; caracterizada pela exist&ecirc;ncia de elevado stress oxidativo, bem como inflama&ccedil;&atilde;o local e sist&eacute;mica, com eleva&ccedil;&atilde;o das concentra&ccedil;&otilde;es plasm&aacute;ticas de citoquinas pr&oacute;-inflamat&oacute;rias, tais como a IL-6, IL-&beta; e TNF-&alpha; (1, 3, 4).</p>     <p>As les&otilde;es articulares mostram infiltra&ccedil;&atilde;o de linf&oacute;citos T, macr&oacute;fagos e plasm&oacute;citos secretores de anticorpos na membrana sinovial. Existe ainda a prolifera&ccedil;&atilde;o de sinovi&oacute;citos. Estas c&eacute;lulas e novos vasos sangu&iacute;neos originam um tecido denominado pannus, que leva &agrave; destrui&ccedil;&atilde;o progressiva da cartilagem e osso. Isto ocorre devido &agrave; indu&ccedil;&atilde;o de enzimas, tais como as metaloprote&iacute;nases mediadas por citocinas e eicosan&oacute;ides. O l&iacute;quido sinovial de indiv&iacute;duos com AR cont&eacute;m n&iacute;veis elevados de citocinas pro-inflamat&oacute;rias, incluindo fator de necrose tumoral-&alpha; (TNF-&alpha;), interleucina 1-&beta; (IL-&beta;), interleucina-6 (IL-6) e IL-8, bem como fator estimulante de col&oacute;nias de macr&oacute;fagos/granul&oacute;citos (5). Ocorre ainda a ativa&ccedil;&atilde;o da resposta de fase aguda, com a redu&ccedil;&atilde;o da s&iacute;ntese de albumina e aumento da produ&ccedil;&atilde;o de fibrinog&eacute;nio, transferrina, prote&iacute;na C reativa, entre outros.</p>     <p>A inflama&ccedil;&atilde;o sist&eacute;mica origina altera&ccedil;&otilde;es no metabolismo energ&eacute;tico e proteico, fraqueza muscular, fadiga intensa e aumento do tecido adiposo, em particular da gordura visceral. Esta condi&ccedil;&atilde;o ocorre independentemente de uma adequada ou excessiva ingest&atilde;o alimentar e &eacute; normalmente vista na presen&ccedil;a de hipermetabolismo e hipercatabolismo, associado a baixa atividade f&iacute;sica (1, 4, 6, 7). Por norma, indiv&iacute;duos com AR apresentam diferentes graus de m&aacute; nutri&ccedil;&atilde;o: m&aacute; absor&ccedil;&atilde;o, anorexia e perda de peso por perda de massa magra (6, 7), sendo observado frequentemente uma reduzida ingest&atilde;o energ&eacute;tica proveniente dos gl&uacute;cidos, elevado consumo de gordura saturada e baixa ingest&atilde;o de micronutrientes, quando comparado com grupos controlo de diversos estudos observacionais (1, 6, 8). Contudo, ainda n&atilde;o &eacute; claro o mecanismo pelo qual indiv&iacute;duos com AR t&ecirc;m uma m&aacute; nutri&ccedil;&atilde;o (1, 4, 6, 8).</p>     <p>Os tratamentos convencionais para a AR incluem os anti-inflamat&oacute;rios n&atilde;o ester&oacute;ides (AINEs), f&aacute;rmacos antirreum&aacute;ticos de a&ccedil;&atilde;o lenta e cortic&oacute;ides, destinados ao al&iacute;vio dos sintomas e da dor articular, mas tamb&eacute;m como forma de travar a evolu&ccedil;&atilde;o da doen&ccedil;a. N&atilde;o obstante, estas abordagens terap&ecirc;uticas raramente obt&ecirc;m total efic&aacute;cia e algumas terap&ecirc;uticas farmacol&oacute;gicas apresentam o risco de efeitos secund&aacute;rios como a perda de massa &oacute;ssea e hemorragia gastrointestinal (1, 6). Concomitantemente, alguns dos f&aacute;rmacos prescritos na AR podem apresentar propriedades anti nutricionais por aumentarem as necessidades de determinado nutriente, mas tamb&eacute;m por redu&ccedil;&atilde;o da sua absor&ccedil;&atilde;o (1, 4, 6). Dessa forma, investigadores t&ecirc;m vindo a procurar outras &aacute;reas que possam complementar o tratamento convencional para a AR. Diversos trabalhos de investiga&ccedil;&atilde;o sugerem que a nutri&ccedil;&atilde;o pode ter um papel complementar no tratamento da AR, em particular no aux&iacute;lio da redu&ccedil;&atilde;o de sintomas caracter&iacute;sticos da patologia e risco de complica&ccedil;&otilde;es (1, 9-11), assim como eventualmente auxiliar na redu&ccedil;&atilde;o da dose de alguns f&aacute;rmacos, consequentemente reduzindo os seus efeitos secund&aacute;rios (6, 12). Com este trabalho pretende-se fazer uma revis&atilde;o da evid&ecirc;ncia cient&iacute;fica sobre o papel da alimenta&ccedil;&atilde;o e dos principais nutrientes mais indicados no tratamento da AR, na redu&ccedil;&atilde;o da sintomatologia, na diminui&ccedil;&atilde;o da progress&atilde;o da doen&ccedil;a e na redu&ccedil;&atilde;o de efeitos secund&aacute;rios associados &agrave; toma dos f&aacute;rmacos recomendados. Analisou-se tamb&eacute;m os poss&iacute;veis benef&iacute;cios que certos padr&otilde;es alimentares possam trazer a indiv&iacute;duos com AR.</p>     <p><u>Padr&atilde;o alimentar</u></p>     <p>Os indiv&iacute;duos com AR referem frequentemente que os seus sintomas s&atilde;o aliviados por padr&otilde;es alimentares espec&iacute;ficos, ao eliminarem determinados alimentos da dieta ou ap&oacute;s per&iacute;odos de jejum. Alguns estudos demonstram que a pr&aacute;tica da alimenta&ccedil;&atilde;o mediterr&acirc;nica traz benef&iacute;cios a indiv&iacute;duos com AR (13, 14). Este padr&atilde;o alimentar carateriza-se pela sua riqueza em fruta, hort&iacute;colas, cereais inteiros, peixe e azeitonas, bem como pelo baixo consumo de carne vermelha e alimentos com gordura saturada (14, 15). Num estudo demonstrou-se melhorias significativas no perfil lip&iacute;dico de indiv&iacute;duos que aderiram &agrave; alimenta&ccedil;&atilde;o mediterr&acirc;nica de Creta, levando a uma redu&ccedil;&atilde;o da progress&atilde;o da doen&ccedil;a e a uma melhoria da capacidade funcional e vitalidade (12). Um outro estudo mostrou tamb&eacute;m melhorias na redu&ccedil;&atilde;o da progress&atilde;o da AR, bem como melhorias na capacidade funcional e vitalidade (12). Outros investigadores verificaram que os indiv&iacute;duos com AR que aderiram &agrave; alimenta&ccedil;&atilde;o mediterr&acirc;nica apresentavam melhorias na rigidez matinal, na dor e redu&ccedil;&atilde;o da atividade da doen&ccedil;a, em rela&ccedil;&atilde;o ao grupo controlo (13, 16, 17). Pensa-se que o efeito protetor associado &agrave; pr&aacute;tica deste tipo de padr&atilde;o alimentar pode advir do consumo de alimentos ricos em gordura insaturada e antioxidantes (AOX) (15).</p>     <p>V&aacute;rios estudos referem melhorias significativas em v&aacute;rias medidas objetivas e subjetivas, na atividade da AR, incluindo o n&uacute;mero de articula&ccedil;&otilde;es tumefactas, bem como altera&ccedil;&otilde;es em par&acirc;metros bioqu&iacute;micos e imunol&oacute;gicos, consistentes com a redu&ccedil;&atilde;o da atividade inflamat&oacute;ria, quando os indiv&iacute;duos seguiam uma rotina de jejum seguido de uma alimenta&ccedil;&atilde;o vegetariana (4, 18). Outros autores referem que apenas alguns indiv&iacute;duos usufru&iacute;ram de benef&iacute;cios no seguimento de uma alimenta&ccedil;&atilde;o vegetariana e que esta pode ser um complemento da terap&ecirc;utica convencional, uma vez que alguns indiv&iacute;duos apresentaram francas melhorias com o seu uso (4, 16, 19).</p>     ]]></body>
<body><![CDATA[<p>As dietas de elimina&ccedil;&atilde;o baseiam-se na remo&ccedil;&atilde;o de um ou v&aacute;rios alimentos do padr&atilde;o alimentar, que possam estar a agravar a patologia do indiv&iacute;duo com AR. Estes alimentos s&atilde;o posteriormente reintroduzidos com o intuito de perceber se existe o agravamento da sintomatologia do doente (15). H&aacute; aus&ecirc;ncia de consist&ecirc;ncia entre os diversos estudos que t&ecirc;m tentado estudar os efeitos da exclus&atilde;o de alguns alimentos, tais como carnes vermelhas, latic&iacute;nios, cereais e alimentos com gl&uacute;ten, na sintomatologia destes indiv&iacute;duos (1, 16). Caso tenham benef&iacute;cio, ainda n&atilde;o existem provas cient&iacute;ficas para incentivar a remo&ccedil;&atilde;o de um ou v&aacute;rios alimentos do padr&atilde;o alimentar de indiv&iacute;duos com AR. Por norma, as dietas de elimina&ccedil;&atilde;o s&atilde;o precedidas por per&iacute;odos de jejum, o que pode confundir a melhoria dos sintomas, uma vez que o jejum suprime a inflama&ccedil;&atilde;o. O mecanismo pelo qual a inflama&ccedil;&atilde;o acontece ainda n&atilde;o est&aacute; bem compreendido, mas pensa-se que esteja relacionado com a redu&ccedil;&atilde;o da liberta&ccedil;&atilde;o de citocinas pr&oacute;-inflamat&oacute;rias, com a redu&ccedil;&atilde;o da forma&ccedil;&atilde;o de leucotrienos e com as altera&ccedil;&otilde;es da permeabilidade intestinal que podem diminuir a absor&ccedil;&atilde;o de imunoestimulantes pelo intestino (1).</p>     <p>Uma vez que estes indiv&iacute;duos j&aacute; apresentam um estado nutricional comprometido pela dificuldade na aquisi&ccedil;&atilde;o de alimentos e/ou sua prepara&ccedil;&atilde;o/confe&ccedil;&atilde;o, bem como pela evolu&ccedil;&atilde;o da pr&oacute;pria doen&ccedil;a, os efeitos adversos de dietas demasiado restritivas podem tornar-se mais prejudiciais que ben&eacute;ficas (1, 4, 15). De todos os padr&otilde;es alimentares analisados, a dieta mediterr&acirc;nica &eacute; a que, at&eacute; ao momento, demonstra benef&iacute;cios na sua recomenda&ccedil;&atilde;o a indiv&iacute;duos com AR. Contudo, ainda n&atilde;o &eacute; claro que aspeto da dieta &eacute; respons&aacute;vel por tais efeitos observados. Estes benef&iacute;cios podem estar associados ao baixo consumo de carne vermelha ou &agrave; inclus&atilde;o de frutas e vegetais, naturalmente ricos em AOX(1) (20). Atendendo que na maioria dos estudos n&atilde;o foram controladas todas as vari&aacute;veis de forma rigorosa, nomeadamente os efeitos secund&aacute;rios da remo&ccedil;&atilde;o de determinado alimento de um padr&atilde;o alimentar, estes n&atilde;o devem ser interpretados como conclusivos. Mais estudos s&atilde;o necess&aacute;rios para comprovar os benef&iacute;cios de cada padr&atilde;o alimentar acima referido.</p>     <p><u>&Aacute;cidos Gordos Polinsaturados N-3</u></p>     <p>Existe evid&ecirc;ncia cient&iacute;fica, baseada em modelos experimentais e estudos cl&iacute;nicos, que os &aacute;cidos gordos polinsaturados n-3 s&atilde;o ben&eacute;ficos na redu&ccedil;&atilde;o da inflama&ccedil;&atilde;o e no al&iacute;vio dos sintomas da AR (1, 6, 21). Hoje em dia, os pa&iacute;ses industrializados s&atilde;o caracterizados pelo aumento do consumo de alimentos ricos em gordura saturada, &aacute;cidos gordos &oacute;mega-6 (n-6) e &aacute;cidos gordos trans, bem como um decr&eacute;scimo da ingest&atilde;o de n-3 (21). O r&aacute;cio de n-6:n-3 para uma ingest&atilde;o di&aacute;ria adequada deveria ser 1-4:1. Contudo, com as altera&ccedil;&otilde;es alimentares acima descritas nos pa&iacute;ses ocidentais, o r&aacute;cio aumentou para valores entre 10:1 a 20:1. Garantir um r&aacute;cio n-6:n-3 adequado &eacute; desej&aacute;vel para reduzir o risco de doen&ccedil;as inflamat&oacute;rias cr&oacute;nicas (1, 21). Aumentar a propor&ccedil;&atilde;o de &aacute;cido gordo eicosapentaen&oacute;ico (EPA) na membrana fosfolip&iacute;dica n&atilde;o s&oacute; reduz os n&iacute;veis de &aacute;cido araquid&oacute;nico (AA) dispon&iacute;vel para ser metabolizado pela via das lipoxigenases e cicloxigenases, como tamb&eacute;m afeta a fun&ccedil;&atilde;o celular e a produ&ccedil;&atilde;o de percursores de eicosan&oacute;ides (1, 6). Estes &uacute;ltimos est&atilde;o entre os principais mediadores e reguladores da inflama&ccedil;&atilde;o, s&iacute;ntese de citoquinas e comunica&ccedil;&atilde;o celular (1, 5). O metabolismo dos &aacute;cidos gordos n-6 produz AA, levando &agrave; produ&ccedil;&atilde;o de leucotrienos, prostaglandinas e tromboxanos da s&eacute;rie 2 e 4, enquanto o metabolismo do EPA e do &aacute;cido docosahexaen&oacute;ico (DHA) formam os respetivos eicosan&oacute;ides das s&eacute;ries 3 e 5 ( 1). O EPA e o DHA possuem a capacidade de diminuir a produ&ccedil;&atilde;o de eicosan&oacute;ides derivados do AA e diminuir a produ&ccedil;&atilde;o de citocinas pro-inflamat&oacute;rias TNF-&alpha;, IL-1&beta; e IL-6, diminuindo a prolifera&ccedil;&atilde;o de linf&oacute;citos e esp&eacute;cies reativas de oxig&eacute;nio (ERO) (1, 5, 21). O mecanismo pelo qual os &aacute;cidos gordos polinsaturados (PUFA) atuam ainda est&aacute; em discuss&atilde;o, mas sabe-se que demonstram propriedades anti-inflamat&oacute;rias. Serhan et al. descobriram recentemente que os n-3 PUFA (EPA e DHA) podem ser enzimaticamente convertidos in vivo em novos mediadores lip&iacute;dicos bioativos, designados por resolvinas, protectinas e maresinas, que promovem a resolu&ccedil;&atilde;o da inflama&ccedil;&atilde;o. Parece que estes &uacute;ltimos, s&atilde;o mais potentes que os seus precursores lip&iacute;dicos. Existe evid&ecirc;ncia emergente da utiliza&ccedil;&atilde;o das resolvinas como agentes antiartr&iacute;ticos, mostrando ainda efeitos anti-inflamat&oacute;rios, capacidade de resolu&ccedil;&atilde;o e a&ccedil;&atilde;o analg&eacute;sica em modelos experimentais de doen&ccedil;as (22).</p>     <p>Diversos estudos t&ecirc;m analisado a efic&aacute;cia da suplementa&ccedil;&atilde;o com &oacute;leos de peixe, ricos em n-3 na AR. Nos estudos que incluem a utiliza&ccedil;&atilde;o de suplementa&ccedil;&atilde;o com &aacute;cidos gordos polinsaturados (essencialmente n-3 PUFA) os autores concluem que, entre os efeitos terap&ecirc;uticos encontrados destacam-se a redu&ccedil;&atilde;o da utiliza&ccedil;&atilde;o de AINEs e a redu&ccedil;&atilde;o da dor (5, 23). A meta-an&aacute;lise feita por Lee et al. sugere que a ingest&atilde;o de n-3 em dosagens superiores a 2,7 g/dia, durante mais de 3 meses, pode auxiliar na redu&ccedil;&atilde;o do uso de AINEs em indiv&iacute;duos com AR. Galaranga et al. apontam para uma suplementa&ccedil;&atilde;o oral de 2,2 g por dia de EPA e DHA, para redu&ccedil;&atilde;o do uso de AINEs para um ter&ccedil;o, sem haver preju&iacute;zo da atividade da doen&ccedil;a (23). Outros trabalhos sugerem o consumo de 1,6 a 7,1 g/dia de n-3 (22, 24, 25). Esta descoberta &eacute; importante no que diz respeito aos efeitos secund&aacute;rios dos AINEs, que s&atilde;o dos f&aacute;rmacos mais prescritos aos indiv&iacute;duos com AR. Os AINEs s&atilde;o conhecidos por estarem associados a altera&ccedil;&otilde;es gastrointestinais, ao aumento da tens&atilde;o arterial, ao aumento do risco de paragem card&iacute;aca e ao aumento do risco cardiovascular (26). Calder et al. sugerem que a efetividade dos &oacute;leos de peixe pode estar subestimada em diversos trabalhos de investiga&ccedil;&atilde;o, uma vez que em diversos estudos, os indiv&iacute;duos com AR continuavam com a terap&ecirc;utica farmacol&oacute;gica, para al&eacute;m da suplementa&ccedil;&atilde;o com os &oacute;leos de peixe, entre outras limita&ccedil;&otilde;es associadas aos estudos (1, 21, 25). Em s&iacute;ntese, a suplementa&ccedil;&atilde;o com n-3 PUFA tem demonstrado de forma modesta, a capacidade de modular a atividade de fatores inflamat&oacute;rios que causam destrui&ccedil;&atilde;o da cartilagem na AR, beneficiar na tumefa&ccedil;&atilde;o e dor articular, na rigidez matinal, na atividade da doen&ccedil;a e reduzir o uso de f&aacute;rmacos AINEs (5, 7, 21, 22, 26). Mais estudos s&atilde;o necess&aacute;rios para estabelecer conclus&otilde;es definitivas relativamente &agrave; quantidade de n-3 indicada por dia e confirmar os efeitos cl&iacute;nicos advenientes do uso de suplementa&ccedil;&atilde;o com n-3 PUFA na RA.</p>     <p><u>Vitaminas e minerais</u></p>     <p>O stress oxidativo desempenha um papel importante n&atilde;o s&oacute; na patog&eacute;nese das doen&ccedil;as reum&aacute;ticas autoimunes, mas tamb&eacute;m nas complica&ccedil;&otilde;es associadas e na atividade da AR. Na AR, as ERO e outros radicais livres est&atilde;o associados a processos inflamat&oacute;rios de numerosas vias metab&oacute;licas. Durante a inflama&ccedil;&atilde;o, a oxida&ccedil;&atilde;o modifica as lipoprote&iacute;nas de baixa densidade, inativa o inibidor da &alpha;-1-protease, danifica o ADN e causa peroxida&ccedil;&atilde;o lip&iacute;dica. As ERO tamb&eacute;m danificam a cartilagem, a matriz extracelular e inibem a s&iacute;ntese de colag&eacute;nio e proteoglicanos. Desta forma, o desequil&iacute;brio entre as mol&eacute;culas pr&oacute; e anti-inflamat&oacute;rias, derivado de altera&ccedil;&otilde;es no equil&iacute;brio entre oxidantes/AOX, pode desempenhar um papel na patofisiologia das doen&ccedil;as reum&aacute;ticas autoimunes (1, 27-30). V&aacute;rios estudos t&ecirc;m procurado demonstrar a efic&aacute;cia do uso de AOX na AR. Todavia, a sua qualidade foi considerada bastante fraca. Da mesma forma, estudos sobre a rela&ccedil;&atilde;o entre o benef&iacute;cio da utiliza&ccedil;&atilde;o de vitamina A, C, e E, quercetina, &aacute;cido &alpha;-lip&oacute;lico, glutationa e zinco na AR originaram resultados contradit&oacute;rios provenientes de uma metodologia que, na maioria dos casos, era pobre. Nestes estudos estavam inclu&iacute;dos estudos de curta e longa dura&ccedil;&atilde;o e n&atilde;o foram utilizadas medidas diretas de avalia&ccedil;&atilde;o da dor. Assim, concluiu-se que n&atilde;o existe evid&ecirc;ncia cient&iacute;fica para a utiliza&ccedil;&atilde;o de AOX na AR (1, 27, 29, 31, 32). N&atilde;o obstante, j&aacute; foi reportado, em diversos estudos de coorte, uma associa&ccedil;&atilde;o entre um elevado consumo de fruta e hort&iacute;colas e um reduzido risco de desenvolver AR. Indiv&iacute;duos com AR devem ser incentivados a atingir as recomenda&ccedil;&otilde;es dos AOX, atrav&eacute;s do consumo de hortofrut&iacute;colas (1, 20). Contudo, estes resultados podem ser question&aacute;veis devido ao reduzido n&uacute;mero de estudos existentes.</p>     <p>Na AR, &eacute; frequentemente prescrito o metotrexato, um f&aacute;rmaco anti-reum&aacute;tico, antagonista dos n&iacute;veis de folato. Nos indiv&iacute;duos que fazem metrotrexato, os n&iacute;veis de folato tamb&eacute;m est&atilde;o diminu&iacute;dos, sugerindo que esta car&ecirc;ncia nutricional est&aacute; relacionada com a toxicidade do metotrexato (1). Foi mostrado o efeito ben&eacute;fico da suplementa&ccedil;&atilde;o com folato em indiv&iacute;duos com AR durante o tratamento com metotrexato, com uma redu&ccedil;&atilde;o significativa da incid&ecirc;ncia de efeitos secund&aacute;rios gastrointestinais e disfun&ccedil;&atilde;o hep&aacute;tica (33-35).</p>     <p>Aproximadamente 1/3 dos casos de anemia em indiv&iacute;duos com AR pode ser causado pela deple&ccedil;&atilde;o das reservas de ferro. A anemia resultante da defici&ecirc;ncia de ferro pode provir da inflama&ccedil;&atilde;o cr&oacute;nica e das perdas de sangue gastrointestinais, causadas pela medica&ccedil;&atilde;o para a AR. Todavia, n&atilde;o existe at&eacute; &agrave; data evid&ecirc;ncia para a suplementa&ccedil;&atilde;o com ferro em indiv&iacute;duos com AR (1).</p>     <p>A evid&ecirc;ncia cient&iacute;fica sugere que uma defici&ecirc;ncia em vitamina D pode desencadear uma resposta autoimune e que n&iacute;veis apropriados de vitamina D possuem um efeito imunossupressor. V&aacute;rios s&atilde;o os estudos a comprovar o benef&iacute;cio da suplementa&ccedil;&atilde;o com vitamina D em indiv&iacute;duos com AR, com n&iacute;veis reduzidos desta vitamina e com uma fase ativa da doen&ccedil;a, como forma de diminuir a presen&ccedil;a de mediadores pro-inflamat&oacute;rios (36-38). Uma metan&aacute;lise recente estabeleceu a associa&ccedil;&atilde;o entre os n&iacute;veis de vitamina D e a atividade da AR. Song et al. reportam que existe uma associa&ccedil;&atilde;o inversa entre a atividade da AR e os n&iacute;veis s&eacute;ricos de vitamina D. Recentemente um estudo conduzido por Sabbagh et al. revela que concentra&ccedil;&otilde;es baixas de vitamina D, avaliadas sob a forma de 25(OH)D propiciam um risco cinco vezes superior de desenvolver AR (38). Chandrashekara et al. verificaram que a suplementa&ccedil;&atilde;o com vitamina D em indiv&iacute;duos com AR, com car&ecirc;ncia de vitamina D e que possu&iacute;am a doen&ccedil;a ativa melhorou significativamente a atividade da doen&ccedil;a, num curto intervalo de tempo (39). Contudo, mais estudos s&atilde;o necess&aacute;rios para perceber se os n&iacute;veis de 25(OH)D s&atilde;o uma causa ou consequ&ecirc;ncia da AR (40).</p>     ]]></body>
<body><![CDATA[<p><u>Probi&oacute;ticos</u></p>     <p>Existe evid&ecirc;ncia em estudos feitos em humanos que a flora intestinal de indiv&iacute;duos com AR encontra-se alterada e que o seu desequil&iacute;brio pode contribuir para o aparecimento desta doen&ccedil;a (6, 41, 42). Os probi&oacute;ticos s&atilde;o microrganismos vivos, que quando administrados a um indiv&iacute;duo, em quantidades adequadas, conferem benef&iacute;cios em termos de sa&uacute;de. Exercem efeitos localmente quer no trato gastrointestinal, pela modula&ccedil;&atilde;o da flora intestinal residente, quer fora, nomeadamente nas articula&ccedil;&otilde;es, pulm&atilde;o e pele. Os efeitos indiretos ocorrem provavelmente pelas altera&ccedil;&otilde;es imunit&aacute;rias e pela altera&ccedil;&atilde;o de mediadores inflamat&oacute;rios, como as citoquinas (6). Num estudo feito por Vaghef-Mehrabany et al., procurou-se analisar os benef&iacute;cios dos probi&oacute;ticos em 46 indiv&iacute;duos com AR, durante 8 semanas, como forma de controlo da atividade da doen&ccedil;a. Com este estudo, demonstraram que a suplementa&ccedil;&atilde;o com L casei 01 pode melhorar o estado inflamat&oacute;rio e a atividade da doen&ccedil;a dos indiv&iacute;duos com AR, sugerindo que, caso estes resultados sejam confirmados por outros estudos, seria ben&eacute;fico utilizar como terap&ecirc;utica adjuvante neste tipo de patologia (41).</p>     <p>No entanto, at&eacute; ao momento, n&atilde;o existe um consenso quanto &agrave; atividade dos probi&oacute;ticos no estado inflamat&oacute;rio e atividade da AR. Existem estudos que nos mostram seguran&ccedil;a e benef&iacute;cios na utiliza&ccedil;&atilde;o de outras estirpes de probi&oacute;ticos, como o Bacillus coagulans GBI-30 em indiv&iacute;duos com AR, como forma de melhorar a sintomatologia (43). Outros trabalhos de investiga&ccedil;&atilde;o, com outras estirpes de probi&oacute;ticos mostram que n&atilde;o se verificaram diferen&ccedil;as estatisticamente significativas na atividade da AR com a utiliza&ccedil;&atilde;o de probi&oacute;ticos (44, 45). Assim sendo, refor&ccedil;a-se a necessidade de se conduzirem mais estudos, com outras estirpes de probi&oacute;ticos, durante um per&iacute;odo mais alargado e com diferentes dosagens para um melhor conhecimento nesta &aacute;rea.</p>     <p><b>AN&Aacute;LISE CR&Iacute;TICA E CONCLUS&Otilde;ES</b></p>     <p>Os trabalhos de investiga&ccedil;&atilde;o que analisam o efeito dos padr&otilde;es alimentares e a suplementa&ccedil;&atilde;o nutricional na AR est&atilde;o prejudicados pela presen&ccedil;a de in&uacute;meros fatores confundidores. Os indiv&iacute;duos com AR procuram, com frequ&ecirc;ncia, complementar a terap&ecirc;utica m&eacute;dica institu&iacute;da com modifica&ccedil;&otilde;es alimentares por eles decididas. Estas altera&ccedil;&otilde;es dificultam a sele&ccedil;&atilde;o de um grupo apropriado para estudo. A melhoria dos sintomas pode estar relacionada com a severidade da doen&ccedil;a, bem como o quadro inflamat&oacute;rio subjacente. V&aacute;rios dos estudos cient&iacute;ficos existentes t&ecirc;m uma metodologia pobre relativa &agrave;s manipula&ccedil;&otilde;es diet&eacute;ticas, em particular nas dietas de elimina&ccedil;&atilde;o, conferindo-lhes pouca credibilidade. Atendendo que os indiv&iacute;duos com AR t&ecirc;m normalmente um mau estado nutricional, torna-se importante assegurar uma adequada ingest&atilde;o alimentar. O aconselhamento nutricional deve focar-se em assegurar uma alimenta&ccedil;&atilde;o completa, equilibrada e variada, onde se atinjam as recomenda&ccedil;&otilde;es nutricionais de &aacute;cidos gordos polinsaturados n-3, AOX, vitaminas e sais minerais, de forma a reduzir a severidade da sintomatologia e evolu&ccedil;&atilde;o da AR.</p>     <p>Perante todos estes fatores, a rela&ccedil;&atilde;o entre a AR e o estado nutricional n&atilde;o se encontra totalmente comprovada e precisa de mais clarifica&ccedil;&atilde;o.</p>     <p>S&atilde;o procuradas todas as interven&ccedil;&otilde;es efetivas que possam contribuir para a supress&atilde;o/redu&ccedil;&atilde;o da inflama&ccedil;&atilde;o e aux&iacute;lio no desenvolvimento de tratamentos mais eficazes e simultaneamente menos agressivos para os indiv&iacute;duos com AR, em concord&acirc;ncia com a terap&ecirc;utica m&eacute;dica e farmacol&oacute;gica definida. S&atilde;o necess&aacute;rios mais estudos de interven&ccedil;&atilde;o randomizados e controlados de longa dura&ccedil;&atilde;o para proporcionar evid&ecirc;ncia cient&iacute;fica mais clara, relativa ao impacto da suplementa&ccedil;&atilde;o nutricional e de recomenda&ccedil;&otilde;es alimentares na AR, com vista a reduzir sintomas, melhorar a qualidade de vida destes indiv&iacute;duos, prevenir a doen&ccedil;a cardiovascular e reduzir seus efeitos secund&aacute;rios associados &agrave; terap&ecirc;utica farmacol&oacute;gica institu&iacute;da.</p> </p>     <p>&nbsp;</p>     <p><b >REFER&#202;NCIAS BIBLIOGR&#193;FICAS</b> <ol start="1">     <li>Rennie KL, Hughes J, Lang R, Jebb SA. Nutritional management of rheumatoid arthritis: a review of the evidence. J Hum Nutr Diet. 2003;16(2):97-109.</li>     ]]></body>
<body><![CDATA[<li>Lazaros G, Tousoulis D. Rheumatoid Arthritis and Atherosclerosis: Could Common Pathogenesis Translate Into Common Therapies? Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese. 2015;56(5):414-7.</li>     <li>Chimenti MS, Triggianese P, Conigliaro P, Candi E, Melino G, Perricone R. The interplay between inflammation and metabolism in rheumatoid arthritis. Cell death &amp; disease. 2015;6:e1887.</li>     <li>L A Coleman RR. Arthritis. In: Prentice BCLAA, editor. Encyclopedia of Human Nutrition. 2&ordf; ed. Oxford UK: Elsevier; 2005. p. 163 - 9.</li>     <li>Miles EA, Calder PC. Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. Br J Nutr. 2012;107 Suppl 2:S171-84.</li>     <li>Al-Okbi SY. Nutraceuticals of anti-inflammatory activity as complementary therapy for rheumatoid arthritis. Toxicol Ind Health. 2012.</li>     <li>Hayashi H, Satoi K, Sato-Mito N, Kaburagi T, Yoshino H, Higaki M, et al. Nutritional status in relation to adipokines and oxidative stress is associated with disease activity in patients with rheumatoid arthritis. Nutrition. 2012;28(11-12):1109-14.</li>     <li>Lombard LA, du Plessis LM, Visser J. Body composition of rheumatoid arthritis patients in the City of Cape Town, South Africa. Clin Rheumatol. 2013.</li>     <li>Jalili M, Kolahi S, Aref-Hosseini SR, Mamegani ME, Hekmatdoost A. Beneficial role of antioxidants on clinical outcomes and erythrocyte antioxidant parameters in rheumatoid arthritis patients. International journal of preventive medicine. 2014;5(7):835-40.</li>     <li>Gonzalez Cernadas L, Rodriguez-Romero B, Carballo-Costa L. [Importance of nutritional treatment in the inflammatory process of rheumatoid arthritis patients; a review]. Nutricion hospitalaria. 2014;29(2):237-45.</li>     <li>Silva BN, Araujo IL, Queiroz PM, Duarte AL, Burgos MG. Intake of antioxidants in patients with rheumatoid arthritis. Revista da Associacao Medica Brasileira (1992). 2014;60(6):555-9.</li>     ]]></body>
<body><![CDATA[<li>Hagfors L, Nilsson I, Skoldstam L, Johansson G. Fat intake and composition of fatty acids in serum phospholipids in a randomized, controlled, Mediterranean dietary intervention study on patients with rheumatoid arthritis. Nutr Metab (Lond). 2005;2:26.</li>     <li>Sales C, Oliviero F, Spinella P. [The mediterranean diet model in inflammatory rheumatic diseases]. Reumatismo. 2009;61(1):10-4.</li>     <li>McKellar G, Morrison E, McEntegart A, Hampson R, Tierney A, Mackle G, et al. A pilot study of a Mediterranean-type diet intervention in female patients with rheumatoid arthritis living in areas of social deprivation in Glasgow. Annals of the rheumatic diseases. 2007;66(9):1239-43.</li>     <li>Smedslund G, Byfuglien MG, Olsen SU, Hagen KB. Effectiveness and safety of dietary interventions for rheumatoid arthritis: a systematic review of randomized controlled trials. J Am Diet Assoc. 2010;110(5):727-35.</li>     <li>Li S, Micheletti R. Role of diet in rheumatic disease. Rheum Dis Clin North Am. 2011;37(1):119-33.</li>     <li>Skoldstam L, Hagfors L, Johansson G. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Annals of the rheumatic diseases. 2003;62(3):208-14.</li>     <li>Muller H, de Toledo FW, Resch KL. Fasting followed by vegetarian diet in patients with rheumatoid arthritis: a systematic review. Scand J Rheumatol. 2001;30(1):1-10.</li>     <li>Kjeldsen-Kragh J. Rheumatoid arthritis treated with vegetarian diets. Am J Clin Nutr. 1999;70(3 Suppl):594S-600S.</li>     <li>Boeing H, Bechthold A, Bub A, Ellinger S, Haller D, Kroke A, et al. Critical review: vegetables and fruit in the prevention of chronic diseases. Eur J Nutr. 2012;51(6):637-63.</li>     <li>Patterson E, Wall R, Fitzgerald GF, Ross RP, Stanton C. Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.</li>     ]]></body>
<body><![CDATA[<li>Norling LV, Perretti M. The role of omega-3 derived resolvins in arthritis. Curr Opin Pharmacol. 2013;13(3):476-81.</li>     <li>Galarraga B, Ho M, Youssef HM, Hill A, McMahon H, Hall C, et al. Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatology (Oxford). 2008;47(5):665-9.</li>     <li>Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. 2007;129(1-2):210-23.</li>     <li>Calder PC. Session 3: Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on &lsquo;Nutrition and autoimmune disease&rsquo; PUFA, inflammatory processes and rheumatoid arthritis. Proc Nutr Soc. 2008;67(4):409-18.</li>     <li>Lee YH, Bae SC, Song GG. Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. Arch Med Res. 2012;43(5):356-62.</li>     <li>Canter PH, Wider B, Ernst E. The antioxidant vitamins A, C, E and selenium in the treatment of arthritis: a systematic review of randomized clinical trials. Rheumatology (Oxford). 2007;46(8):1223-33.</li>     <li>Sukkar SG, Rossi E. Oxidative stress and nutritional prevention in autoimmune rheumatic diseases. Autoimmun Rev. 2004;3(3):199-206.</li>     <li>Jaswal S, Mehta HC, Sood AK, Kaur J. Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clinica chimica acta; international journal of clinical chemistry. 2003;338(1-2):123-9.</li>     <li>Mirtaheri E, Gargari BP, Kolahi S, Dehghan P, Asghari-Jafarabadi M, Hajalilou M, et al. Effects of Alpha-Lipoic Acid Supplementation on Inflammatory Biomarkers and Matrix Metalloproteinase-3 in Rheumatoid Arthritis Patients. Journal of the American College of Nutrition. 2015;34(4):310-7.</li>     <li>Bae SC, Jung WJ, Lee EJ, Yu R, Sung MK. Effects of antioxidant supplements intervention on the level of plasma inflammatory molecules and disease severity of rheumatoid arthritis patients. Journal of the American College of Nutrition. 2009;28(1):56-62.</li>     ]]></body>
<body><![CDATA[<li>Rosenbaum CC, O&rsquo;Mathuna DP, Chavez M, Shields K. Antioxidants and antiinflammatory dietary supplements for osteoarthritis and rheumatoid arthritis. Alternative therapies in health and medicine. 2010;16(2):32-40.</li>     <li>Shea B, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014;41(6):1049-60.</li>     <li>van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis and rheumatism. 2001;44(7):1515-24.</li>     <li>van Ede AE, Laan RF, Blom HJ, Boers GH, Haagsma CJ, Thomas CM, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41(6):658-65.</li>     <li>Lo Gullo A, Mandraffino G, Bagnato G, Aragona CO, Imbalzano E, D&rsquo;Ascola A, et al. Vitamin D Status in Rheumatoid Arthritis: Inflammation, Arterial Stiffness and Circulating Progenitor Cell Number. PloS one. 2015;10(8):e0134602.</li>     <li>Neve A, Corrado A, Cantatore FP. Immunomodulatory effects of vitamin D in peripheral blood monocyte-derived macrophages from patients with rheumatoid arthritis. Clinical and experimental medicine. 2014;14(3):275-83.</li>     <li>Sabbagh Z, Markland J, Vatanparast H. Vitamin D status is associated with disease activity among rheumatology outpatients. Nutrients. 2013;5(7):2268-75.</li>     <li>Chandrashekara S, Patted A. Role of vitamin D supplementation in improving disease activity in rheumatoid arthritis: An exploratory study. International journal of rheumatic diseases. 2015.</li>     <li>Jeffery LE, Raza K, Hewison M. Vitamin D in rheumatoid arthritis-towards clinical application. Nature reviews Rheumatology. 2015.</li>     <li>Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A, Sharif SK, Asghari-Jafarabadi M, Zavvari S. Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition. 2014;30(4):430-5.</li>     ]]></body>
<body><![CDATA[<li>Sandhya P, Danda D, Sharma D, Scaria V. Does the buck stop with the bugs?: an overview of microbial dysbiosis in rheumatoid arthritis. International journal of rheumatic diseases. 2015.</li>     <li>Mandel DR, Eichas K, Holmes J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med. 2010;10:1.</li>     <li>Hatakka K, Martio J, Korpela M, Herranen M, Poussa T, Laasanen T, et al. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis-a pilot study. Scand J Rheumatol. 2003;32(4):211-5.</li>     <li>Lomax AR, Calder PC. Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans. Curr Pharm Des. 2009;15(13):1428-518.</li>     </ol>     <p>&nbsp;</p>     <p>  <b ><a href="#topc0">Endere&#231;o para correspond&#234;ncia</a><a name="c0"></a></b> <br/>Joana Pinheiro     <p>Termas de S. Jorge, Lugar da S&eacute;</p>     <p>4509-903 Caldas de S. Jorge</p>     <p><a href="mailto:nutrisuperhealth@gmail.com">nutrisuperhealth@gmail.com</a> </p>     ]]></body>
<body><![CDATA[<p>&nbsp; </p>     <p>Recebido a 2 de setembro de 2015</p>     <p>Aceite a 23 de dezembro de 2015</p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rennie]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jebb]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nutritional management of rheumatoid arthritis: a review of the evidence]]></article-title>
<source><![CDATA[J Hum Nutr Diet]]></source>
<year>2003</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>97-109</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lazaros]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tousoulis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Rheumatoid Arthritis and Atherosclerosis: Could Common Pathogenesis Translate Into Common Therapies?]]></article-title>
<source><![CDATA[Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese]]></source>
<year>2015</year>
<volume>56</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>414-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chimenti]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Triggianese]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Conigliaro]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Candi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Melino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Perricone]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The interplay between inflammation and metabolism in rheumatoid arthritis]]></article-title>
<source><![CDATA[Cell death & disease]]></source>
<year>2015</year>
<volume>6</volume>
<page-range>e1887</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>L A Coleman RR</collab>
<article-title xml:lang="en"><![CDATA[Arthritis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prentice]]></surname>
<given-names><![CDATA[BCLAA]]></given-names>
</name>
</person-group>
<source><![CDATA[Encyclopedia of Human Nutrition]]></source>
<year>2005</year>
<edition>2</edition>
<page-range>163-9</page-range><publisher-loc><![CDATA[Oxford UK ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miles]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Calder]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis]]></article-title>
<source><![CDATA[Br J Nutr]]></source>
<year>2012</year>
<volume>107</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>S171-84</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Okbi]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nutraceuticals of anti-inflammatory activity as complementary therapy for rheumatoid arthritis]]></article-title>
<source><![CDATA[Toxicol Ind Health]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hayashi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Satoi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sato-Mito]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kaburagi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshino]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Higaki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nutritional status in relation to adipokines and oxidative stress is associated with disease activity in patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Nutrition]]></source>
<year>2012</year>
<volume>28</volume>
<numero>11-12</numero>
<issue>11-12</issue>
<page-range>1109-14</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lombard]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[du Plessis]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Visser]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Body composition of rheumatoid arthritis patients in the City of Cape Town, South Africa]]></article-title>
<source><![CDATA[Clin Rheumatol]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jalili]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kolahi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aref-Hosseini]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Mamegani]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Hekmatdoost]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Beneficial role of antioxidants on clinical outcomes and erythrocyte antioxidant parameters in rheumatoid arthritis patients]]></article-title>
<source><![CDATA[International journal of preventive medicine]]></source>
<year>2014</year>
<volume>5</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>835-40</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez Cernadas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Romero]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Carballo-Costa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Importance of nutritional treatment in the inflammatory process of rheumatoid arthritis patients: a review]]></article-title>
<source><![CDATA[Nutricion hospitalaria]]></source>
<year>2014</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>237-45</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
<name>
<surname><![CDATA[Araujo]]></surname>
<given-names><![CDATA[IL]]></given-names>
</name>
<name>
<surname><![CDATA[Queiroz]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Burgos]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Intake of antioxidants in patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Revista da Associacao Medica Brasileira (1992)]]></source>
<year>2014</year>
<volume>60</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>555-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hagfors]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nilsson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Skoldstam]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Johansson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Fat intake and composition of fatty acids in serum phospholipids in a randomized, controlled, Mediterranean dietary intervention study on patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Nutr Metab (Lond)]]></source>
<year>2005</year>
<volume>2</volume>
<page-range>26</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sales]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Oliviero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Spinella]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The mediterranean diet model in inflammatory rheumatic diseases]]></article-title>
<source><![CDATA[Reumatismo]]></source>
<year>2009</year>
<volume>61</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>10-4</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKellar]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Morrison]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[McEntegart]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hampson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tierney]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mackle]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A pilot study of a Mediterranean-type diet intervention in female patients with rheumatoid arthritis living in areas of social deprivation in Glasgow]]></article-title>
<source><![CDATA[Annals of the rheumatic diseases]]></source>
<year>2007</year>
<volume>66</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1239-43</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smedslund]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Byfuglien]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Olsen]]></surname>
<given-names><![CDATA[SU]]></given-names>
</name>
<name>
<surname><![CDATA[Hagen]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effectiveness and safety of dietary interventions for rheumatoid arthritis: a systematic review of randomized controlled trials]]></article-title>
<source><![CDATA[J Am Diet Assoc]]></source>
<year>2010</year>
<volume>110</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>727-35</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Micheletti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Role of diet in rheumatic disease]]></article-title>
<source><![CDATA[Rheum Dis Clin North Am]]></source>
<year>2011</year>
<volume>37</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>119-33</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skoldstam]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hagfors]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Johansson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Annals of the rheumatic diseases]]></source>
<year>2003</year>
<volume>62</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>208-14</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muller]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[de Toledo]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Resch]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Fasting followed by vegetarian diet in patients with rheumatoid arthritis: a systematic review]]></article-title>
<source><![CDATA[Scand J Rheumatol]]></source>
<year>2001</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kjeldsen-Kragh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Rheumatoid arthritis treated with vegetarian diets]]></article-title>
<source><![CDATA[Am J Clin Nutr]]></source>
<year>1999</year>
<volume>70</volume>
<numero>3^sSuppl</numero>
<issue>3^sSuppl</issue>
<supplement>Suppl</supplement>
<page-range>594S-600S</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boeing]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bechthold]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bub]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ellinger]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Haller]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kroke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Critical review: vegetables and fruit in the prevention of chronic diseases]]></article-title>
<source><![CDATA[Eur J Nutr]]></source>
<year>2012</year>
<volume>51</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>637-63</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wall]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzgerald]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Stanton]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Health implications of high dietary omega-6 polyunsaturated Fatty acids]]></article-title>
<source><![CDATA[J Nutr Metab]]></source>
<year>2012</year>
<volume>2012</volume>
<page-range>539426</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norling]]></surname>
<given-names><![CDATA[LV]]></given-names>
</name>
<name>
<surname><![CDATA[Perretti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The role of omega-3 derived resolvins in arthritis]]></article-title>
<source><![CDATA[Curr Opin Pharmacol]]></source>
<year>2013</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>476-81</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galarraga]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Youssef]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[McMahon]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2008</year>
<volume>47</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>665-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Katz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain]]></article-title>
<source><![CDATA[Pain]]></source>
<year>2007</year>
<volume>129</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>210-23</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calder]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Session 3: Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on 'Nutrition and autoimmune disease' PUFA, inflammatory processes and rheumatoid arthritis]]></article-title>
<source><![CDATA[Proc Nutr Soc]]></source>
<year>2008</year>
<volume>67</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>409-18</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Bae]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis]]></article-title>
<source><![CDATA[Arch Med Res]]></source>
<year>2012</year>
<volume>43</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>356-62</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Canter]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Wider]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ernst]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The antioxidant vitamins A, C, E and selenium in the treatment of arthritis: a systematic review of randomized clinical trials]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2007</year>
<volume>46</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1223-33</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sukkar]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Oxidative stress and nutritional prevention in autoimmune rheumatic diseases]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2004</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>199-206</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jaswal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Sood]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Kaur]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antioxidant status in rheumatoid arthritis and role of antioxidant therapy]]></article-title>
<source><![CDATA[Clinica chimica acta; international journal of clinical chemistry]]></source>
<year>2003</year>
<volume>338</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>123-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mirtaheri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gargari]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Kolahi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dehghan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Asghari-Jafarabadi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hajalilou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of Alpha-Lipoic Acid Supplementation on Inflammatory Biomarkers and Matrix Metalloproteinase-3 in Rheumatoid Arthritis Patients]]></article-title>
<source><![CDATA[Journal of the American College of Nutrition]]></source>
<year>2015</year>
<volume>34</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>310-7</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bae]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sung]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of antioxidant supplements intervention on the level of plasma inflammatory molecules and disease severity of rheumatoid arthritis patients]]></article-title>
<source><![CDATA[Journal of the American College of Nutrition]]></source>
<year>2009</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>56-62</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenbaum]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
</person-group>
<collab>O'Mathuna DP.Chavez M.Shields K</collab>
<article-title xml:lang="en"><![CDATA[Antioxidants and antiinflammatory dietary supplements for osteoarthritis and rheumatoid arthritis]]></article-title>
<source><![CDATA[Alternative therapies in health and medicine]]></source>
<year>2010</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>32-40</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shea]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Swinden]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Ghogomu]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Katchamart]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Rader]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2014</year>
<volume>41</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1049-60</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Ede]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Laan]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Rood]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Huizinga]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
</person-group>
<collab>van de Laar MA.van Denderen CJ</collab>
<article-title xml:lang="en"><![CDATA[Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study]]></article-title>
<source><![CDATA[Arthritis and rheumatism]]></source>
<year>2001</year>
<volume>44</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1515-24</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Ede]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Laan]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Blom]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Boers]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Haagsma]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2002</year>
<volume>41</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>658-65</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lo Gullo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mandraffino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bagnato]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Aragona]]></surname>
<given-names><![CDATA[CO]]></given-names>
</name>
<name>
<surname><![CDATA[Imbalzano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<collab>D'Ascola A</collab>
<article-title xml:lang="en"><![CDATA[Vitamin D Status in Rheumatoid Arthritis: Inflammation, Arterial Stiffness and Circulating Progenitor Cell Number]]></article-title>
<source><![CDATA[PloS one]]></source>
<year>2015</year>
<volume>10</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>e0134602</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neve]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Corrado]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cantatore]]></surname>
<given-names><![CDATA[FP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Immunomodulatory effects of vitamin D in peripheral blood monocyte-derived macrophages from patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Clinical and experimental medicine]]></source>
<year>2014</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>275-83</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabbagh]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Markland]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vatanparast]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Vitamin D status is associated with disease activity among rheumatology outpatients]]></article-title>
<source><![CDATA[Nutrients]]></source>
<year>2013</year>
<volume>5</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2268-75</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chandrashekara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Patted]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Role of vitamin D supplementation in improving disease activity in rheumatoid arthritis: An exploratory study]]></article-title>
<source><![CDATA[International journal of rheumatic diseases]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeffery]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Raza]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hewison]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Vitamin D in rheumatoid arthritis-towards clinical application]]></article-title>
<source><![CDATA[Nature reviews Rheumatology]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaghef-Mehrabany]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Alipour]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Homayouni-Rad]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sharif]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Asghari-Jafarabadi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zavvari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Nutrition]]></source>
<year>2014</year>
<volume>30</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>430-5</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandhya]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Danda]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Scaria]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Does the buck stop with the bugs?: an overview of microbial dysbiosis in rheumatoid arthritis]]></article-title>
<source><![CDATA[International journal of rheumatic diseases]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mandel]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Eichas]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Holmes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial]]></article-title>
<source><![CDATA[BMC Complement Altern Med]]></source>
<year>2010</year>
<volume>10</volume>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hatakka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Martio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Korpela]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Herranen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Poussa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Laasanen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis-a pilot study]]></article-title>
<source><![CDATA[Scand J Rheumatol]]></source>
<year>2003</year>
<volume>32</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>211-5</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lomax]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Calder]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans]]></article-title>
<source><![CDATA[Curr Pharm Des]]></source>
<year>2009</year>
<volume>15</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1428-518</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
